In Alzheimer’s disease (AD) models, PDE4 inhibitors improve cognitive function and alleviate depression-like behavior by activating the cAMP/CREB/BDNF pathway, promoting neuroprotection and reducing apoptosis [3,9]. This evidence concerns the gene BDNF and depressive symptom measurement.